[HTML][HTML] Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from …

M Abe, Y Okubo, H Takahashi, K Endo… - Dermatology and …, 2024 - Springer
Introduction Psoriasis involvement in special areas (eg, scalp or nails) is associated with a
great disease burden yet it is often inadequately treated with topical treatments. The efficacy …

Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from …

M Abe, Y Okubo, H Takahashi, K Endo… - Dermatology and …, 2024 - europepmc.org
Methods In PROMINENT, patients received apremilast 30 mg twice daily for 16 weeks in
addition to their existing topical therapy, with the option of topical therapy reduction at the …

[HTML][HTML] Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from …

M Abe, Y Okubo, H Takahashi, K Endo… - Dermatology and …, 2024 - ncbi.nlm.nih.gov
Methods In PROMINENT, patients received apremilast 30 mg twice daily for 16 weeks in
addition to their existing topical therapy, with the option of topical therapy reduction at the …

Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from …

M Abe, Y Okubo, H Takahashi, K Endo… - Dermatology and … - pubmed.ncbi.nlm.nih.gov
Introduction Psoriasis involvement in special areas (eg, scalp or nails) is associated with a
great disease burden yet it is often inadequately treated with topical treatments. The efficacy …